Gestational trophoblastic neoplasia-pathogenesis and potential therapeutic targets

Research output: Contribution to journalReview article

Abstract

Gestational trophoblastic neoplasia comprises a unique group of human neoplastic diseases that derive from fetal trophoblastic tissues and represent semiallografts in patients. This group is composed of choriocarcinoma, placental-site trophoblastic tumour, and epithelioid trophoblastic tumour, and many forms are derived from the precursor lesions, hydatidiform moles. Although most patients with gestational trophoblastic neoplasia are cured by chemotherapy and tumour resection, some patients suffer from metastatic diseases that are refractory to conventional chemotherapy. Therefore, new therapeutic regimens are needed to reduce the toxic effects associated with current chemotherapy and to salvage the occasional non-operable patients with recurrent and chemoresistant disease. Until the fundamental biology of gestational trophoblastic neoplasia becomes more clearly understood, development of a new treatment will remain empirical. This review will briefly summarise the recent advances in understanding the molecular aetiology of this group of diseases and highlight the molecules that can be potentially used for therapeutic targets to treat metastatic gestational trophoblastic neoplasia.

Original languageEnglish (US)
Pages (from-to)642-650
Number of pages9
JournalLancet Oncology
Volume8
Issue number7
DOIs
StatePublished - Jul 1 2007

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Gestational trophoblastic neoplasia-pathogenesis and potential therapeutic targets'. Together they form a unique fingerprint.

  • Cite this